UPLIFT reassures some over Spiriva CV safety

Boehringer Ingelheim/Pfizer's leading COPD treatment Spiriva (tiotropium bromide) failed to reduce the rate of decline in FEV1 over four years of treatment, the results of the large, long-term UPLIFT study show, but the researchers have found positive effects from the drug and the data have provided some reassurance over the its cardiovascular safety, the subject of great scrutiny in recent weeks.